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ABSTRACT: 
Trisomy for human chromosome 21 (Hsa21) results in Down Syndrome (DS), one of the 
most genetically complex conditions that is compatible with human survival. Up to half 
of DS conceptions do not survive to term. Effects of over-expression of individual Hsa21 
genes that occur during embryogenesis are difficult to study in mammals. We created a 
gene expression set of 171 Hsa21 cDNAs. RNA was transcribed from cDNA and injected 
into 1-2 cell zebrafish embryos which were screened at 5 days post-fertilization for gross 
morphological effects.  Twenty-three genes gave an initial phenotype and ten of those 
genes robustly recapitulated the phenotype in subsequent experiments.  Seven of these 
gave a phenotype consistent with down regulation of the sonic hedgehog (Shh) pathway, 
two showed a phenotype that indicated involvement of neural crest cells, and one showed 
pericardial edema.  We performed combinatorial injections with multiple Hsa21 genes 
and found both additive and compensatory effects. This system and gene set supports 
many types of examination of multiple gene effects on early vertebrate development that 
are relevant to DS.  
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CHAPTER 1: INTRODUCTION 
History of DS 
In 1838, Étienne Esquirole described a congenital form of cognitive impairment in a 
number of patients that included a physical description of short stature and a broad 
flattened nose, which is the first description of Trisomy 21 [1]. Edouard Séguin, in 1846, 
expanded upon Esquirole’s observations with a description of open mouth and thick 
protruding tongue [2,3]. In an essay written in 1866, J. Langdon Down discussed a 
population of individuals with congenital cognitive impairment, as well as characteristic 
facial features [4]. DS was found to be caused by trisomy of human chromosome 21 
(Hsa21) in 1959 by Lejeune, Gautier and Turpin [2]. In 1961, the condition that was 
independently described by Esquirole, Séguin and Down would be renamed Down 
Syndrome (DS), and is now also referred to as Trisomy 21 [2].  
 
Clinical features of DS 
The initial features described by Esquirole, Séguin and Down centered around the facial 
features and the cognitive impairment.  Now, DS is recognized as having >80 clinical 
features, including cognitive impairment, short stature, and characteristic facial features 
[5]. These features affect many systems and vary in penetrance and expressivity. Many 
features occur at birth and during early infancy, such as the facial features and the 
increased risk of congenital heart defects and Hirschprung’s disease; others occur later, 
such as the increased risk of Alzheimer’s disease [6]. 
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The variability of penetrance and expressivity of the phenotypes associated with DS has 
led to the hypothesis that although trisomy 21 is a large risk factor for the development of 
these phenotypes, it is not sufficient for some of these phenotypes, meaning that there are 
modifiers of the DS phenotypes [7].  These modifiers may interact with one or a few 
genes on Hsa21.  Understanding how the different genes on Hsa21 may contribute to the 
different phenotypes associated with DS will help in the pursuit of therapeutic targets for 
ameliorating the condition. 
 
Genetic content of Hsa21  
It was first suggested that Down Syndrome was caused by a chromosomal abnormality in 
1932 by both Waardenburg as well as independently by Davenport [8,9]. In 1959, the 
chromosomal basis for Down Syndrome was established by Lejeune, Gautier and Turpin, 
who used cytogenic techniques to determine that individuals with Down Syndrome had 
an extra copy of chromosome 21 [2]. The nearly complete DNA sequence of Hsa21 was 
published in May of 2000, with an estimate of 225 genes and 59 pseudogenes [10]. 
 
Hsa21 is one of the smallest autosomes with an approximately 33.6 MB long arm, 
representing ~1% of the total human genome [7]. Since the original publication, estimates 
of the genetic content of Hsa21 have ranged from ~200-500 genes, with the most recent 
estimate of 552 genes (excluding KRTAP genes, of which there ~49) [7,10,11,12]. These 
genes include 161 genes that unambiguously code for proteins, i.e. they have a RefSeq 
Protein associated, five microRNAs, 250 open reading frames (ORF) in which the ORFS 
encode a protein >50 amino acids, and 140 ORF with <50 amino acids [12].  In 2007, it 
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was estimated that of the 430 genes reported, approximately 45% had no identified 
function [13].  When considering just the genes that are conserved with mouse, ~14% had 
no functional annotation [11]. Understanding the function and the role these genes may 
play in the development of DS could lead to identification of pathways and targets for 
therapeutic treatment. 
 
Creating genotype-phenotype correlations 
One method of identifying genes that may play significant roles in the presentation of DS 
phenotypes is to look at small duplications/trisomies in individuals and compare that to 
the phenotypes exhibited by those individuals. By examining patients with partial 
trisomies and correlating the trisomic regions with the presentation of DS phenotypes, 
researchers determined the location of the so-called “Down Syndrome Critical Region” 
(DSCR, originally called Down Syndrome Critical Region 1) which includes the region 
D21S55-MX1 or D21S55-CRYAA1, located at 21q22.2-21q22.3 [14,15].  However, 
other phenotypic mapping using partial trisomies has indicated that genes outside the 
D21S55 region also contribute to the DS phenotypes, and individuals with clinical 
features of DS have been identified who have partial trisomy 21 that does not include 
D21S55 [16].   
 
Although the DSCR is not responsible for all of the DS phenotypes, the next option is to 
look for regions that have strong contributions for specific phenotypes.  To develop a 
phenotypic map of Hsa21, Korenberg and colleagues used 16 patients with partial 
Trisomy 21 to attempt to create a phenotypic map of 25 DS features.  Their data suggest 
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that for most of the DS features, multiple gene clusters contribute to the presentation and 
variability [16].   
 
Interest in developing a high resolution phenotypic map has not waned.  In 2009 Korbel 
and colleagues [17] made another attempt at a phenotypic map using 30 patients with 
partial Trisomy 21 and examined 8 major features of DS, including CHD, cognitive 
impairment, acute megakaryocytic leukemia (AMKL), transient myeloproliferative 
disorder (TMD), Hirschsprung’s disease (HSCR), duodenal stenosis (DST), imperforate 
anus (IA) and Alzheimer disease (AD).  In the case of certain features (namely AMKL, 
DST, IA) only a single patient was identified with each feature.  This limitation in 
combination with the observation that some of these patients had complex 
rearrangements involving duplications, deletions and inversions, as well as some 
tetrasomic regions, makes analysis of the possible critical regions of specific features 
complicated.  The authors determined that a 1.77 MB region of Hsa21 is responsible for 
the CHD observed in patients.  However, not every patient that was trisomic for that 
region had CHD, indicating that the region is not sufficient to cause CHD.   
 
Another group in the same year attempted a similar study with 19 individuals with partial 
trisomy 21, investigating 25 DS features [18].  However, for many of the features 
observed, the patients who had the observed feature didn’t overlap in their trisomic 
regions, and there were many examples of individuals who did overlap who did not have 
that particular feature.   
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Although the concept of finding genes that may play larger roles in the development of 
DS phenotypes is valuable, the message to take away from these studies is that DS is too 
complex to assign a single causative region or gene to each character. That complexity 
means that using human patients to model the condition has limitations in the obtaining a 
large enough sample of individuals with partial trisomy 21 for different regions of the 
chromosome that would allow for the identification of genes that may have a function in 
some of the DS features.  At the moment, there aren’t enough partial trisomy 21 patients 
to adequately develop a comprehensive phenotype map, and although that might change 
in the future; at present, animal models are a better option for these types of studies. 
 
Modeling DS in mice 
Understanding how Hsa21 genes function during embryogenesis and how trisomy of 
those genes cause DS phenotypes is not something that can be undertaken in a 
comprehensive manner in humans.  Animal models are necessary to elucidate the manner 
in which trisomy 21 causes DS. The best known and most widely used models of DS are 
available in the mouse. Mice make for a useful model due to the extensive conserved 
synteny between human and mouse chromosomes.  Hsa21 (33.5 Mb) has conserved 
synteny with mouse chromosomes 10 (2.3 Mb), 16 (23.2 Mb) and 17 (1.1 Mb; Mmu10, 
Mmu16 and Mmu17 respectively) [11,19,20,21,22].   
 
Current estimates of genetic content on both Hsa21 and the homologous mouse regions 
put the number of genes at 552 and 436 genes respectively [12].  Of those genes, 166 are 
considered to be highly conserved (including the 5 microRNAs but excluding the 
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KRTAP genes), of which 162 have associated RefSeqP annotation [12].  There are an 
additional four RefSeqP genes that are mouse specific that are within the conserved 
syntenic regions.  There are 274 non-RefSeqP genes in the mouse and 390 non-RefSeqP 
genes in the human that do not have apparent homology.  Sturgeon and Gardiner [12] 
BLASTed the gene transcripts against the genomic region where the gene would be 
predicted to exist (based on neighboring genes that are conserved) and identified an 
additional 139 Hsa21 genes that have sequence conservation to regions of the mouse 
genome and 165 Mmu genes that have sequence conservation to regions of Hsa21 that 
are not represented in the list of 166 highly conserved genes [12].  This indicates that our 
parameters for determining highly conserved genes may be so strict that some 
conservation is being missed.  These genes could have functional consequences that 
should be considered when looking at gene conservation. 
 
Trisomic mouse models of DS 
The large degree of conserved synteny supported the development of mouse models of 
DS.  Multiple models have been developed, with varying amounts of trisomy of the 
regions that have conserved synteny with Hsa21.  One of the first models was Ts16, in 
which the entire Mmu16 was trisomic due to a Robertsonian translocation [23].  This 
model had its limitations due to the fact that more than just the Hsa21 conserved regions 
were trisomic.  The mice showed nervous system abnormalities that are similar to DS but 
the Ts16 pups were neonatal lethal, limiting their utility [24]. 
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The most well studied model is Ts65Dn, a mouse model with a freely segregating 
chromosome consisting of a translocation between the centromeric portion of Mmu17 
with the distal portion of Mmu16 (which contains the region that has conserved synteny 
with Hsa21 [7,23,25]). These mice are trisomic for 110 genes that are highly conserved 
with Hsa21 [26].  This model develops learning and memory deficits that are analogous 
to DS, as well as having a reduced cerebellum similar to individuals with DS [25,27].  In 
addition, the Ts65Dn mice develop craniofacial abnormalities that are analogous to the 
craniofacial features of DS [28].   
 
There are other models with smaller segmental regions, Ts1Cje and Ts1Rhr, which 
contain fewer genes that are conserved with Hsa21, still within the Mmu16 conserved 
region.  In these reduced trisomic models, the severity of the cerebellar phenotype varies 
based on the total trisomic content [29].  By using combinations of these models, we can 
narrow down regions of interest for different DS phenotypes.   
 
Use of various mouse models with different amounts of trisomic gene content have been 
used to more precisely define contributions of different genetic segments to specific 
phenotypes [24,30], but even the smallest segmental trisomic mouse model still contains 
many genes.  A few transgenic mouse models made for individual genes have been used 
to study the effects of gene dosage imbalance of single genes as they relate to DS [24], 
but these transgenic models are costly and time consuming to make and so have only 
been made for candidate genes that were suspected to have a large effect.  The time, 
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effort and cost to make transgenic models for all the highly conserved genes on Hsa21 
are prohibitive to using this approach in an unbiased manner. 
 
Using zebrafish as a model system 
The ability to study early developmental anomalies presents another limitation of mouse 
models.  In order to study developmental stages in mice, a pregnant female has to be 
euthanized, and the embryos removed and fixed.  Each stage requires a separate litter, 
increasing the cost and time if the intent is to look at multiple stages of development.  
There are now methods for ex-vivo imaging of mouse embryos, predominately for use in 
embryos 6-10 days post-coitum (dpc), but only for up to 24 hours of culturing, and these 
methods are very sensitive to environmental control (even small shifts in temperature can 
be detrimental) and still require fixing of the embryos after 12-24 hours of imaging and 
still don’t have the necessary resolution [31,32]. The resolution of these techniques are 
still not enough for use in studying specific organs and tissues. 
 
In contrast, zebrafish make an attractive model for studying early development.  External 
fertilization and a large number of progeny allow for large scale screening of early 
development  [33].  Most organ systems develop within the first 24 hours, and by 5 days 
post-fertilization (DPF) the embryos are free swimming [34].  The transparency of the 
zebrafish embryo adds to its utility, allowing for the visualization of tissue and organ 
development as a whole organism in real time, avoiding the necessity of fixing and 
sectioning in order to examine the internal structures as in mice [35].  This in turn allows 
for the ability to follow a single embryo throughout early development, making zebrafish 
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a powerful model system for studying the effects of Hsa21 gene expression during 
embryogenesis.  Additionally, in zebrafish the craniofacial development parallels the 
development in higher vertebrates [36]. There are many transgenic reporter lines for 
specific cell types and tissues [34,37,38].  
 
A major difficulty in understanding DS is that trisomy 21 originates prior to fertilization, 
with every cell trisomic for Hsa21, causing downstream effects throughout development.  
The trisomic genes could have an primary effect directly on the cellular function due to 
over-expression of a dosage sensitive gene, or could have a secondary effect on the 
expression and regulation of disomic genes that then have further downstream actions 
[27].  The ability to make distinctions between these possibilities would be useful when 
attempting to ameliorate the phenotypes in DS as correcting a single dosage sensitive 
gene would be potentially easier than correcting a pathway that must be carefully 
regulated. Since many aspects of DS develop during embryogenesis, zebrafish allow for 
the analysis of expression of Hsa21 genes during early development.  To facilitate the 
development of genotype-phenotype correlations, I have used zebrafish as a model 
system to study the effects of over-expression of Hsa21 genes during early development. 
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CHAPTER 2: CREATION OF THE HUMAN CHROMOSOME 21 GENE 
EXPRESSION CLONE-SET 
Introduction:  
We sought to develop a Hsa21 gene expression clone-set that would be useful in both in 
vivo and in vitro studies.  Our goal was to develop gene expression set that could be 
cloned into a vector system that was versatile and efficient, containing a set of genes from 
Hsa21 that, while not comprehensive of the total gene list, would comprise the majority 
of genes that might be of interest to the DS community. 
 
The vector system we chose was the Invitrogen Gateway recombination system [39].  
This vector system uses an entry vector plasmid containing attL sites on either side of 
restriction digest cloning sites.  These sites can specifically recombine with attR sites 
located on destination vectors, allowing for easy and efficient sub-cloning of cDNAs 
from the entry vector into any number of destination vectors.  The destination vectors 
contain a ccdB cassette that is toxic to most standard bacterial cells flanked by attR sites. 
Using LR clonase (an excisionase) along with an integrase from bacteriophage delta and 
an integration host factor, the attL sites recombine with the attR sites, resulting in the two 
plasmids: the expression plasmid that contains the ORF of interest flanked by attB sites 
and the former entry vector which contains the lethal ccdB cassette flanked by attP sites 
(so only the expression vector will propagate in standard bacterial cells).  
 
The sub cloning can be performed in 96-well plates, making this system efficient for 
large gene sets. There are a number of destination vector systems that would be useful for 
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the DS community.  Many destination vectors include tags at the 3’ or 5’ ends, as well as 
other modifications, and different promoters are available for expression in both cell 
culture plasmid vectors as well as vectors for use in zebrafish [35].   
 
In this study we obtained or sub-cloned 169 Hsa21 genes (171 cDNAs, two genes are 
represented by two isoforms) into the Invitrogen Gateway recombination system, and 
then sub cloned into the pCS+ destination vector which contains both a CMV promoter 
for expression in mammalian cell culture as well as an SP6 promoter and SV-40 poly-A 
tail for use in vitro RNA transcription. 
 
Methods:  
Hsa21 Gene Expression Library preparation 
Genes from Hsa21 included in the library were curated from lists of genes conserved 
between human and mouse [11,12].  For 120 genes, plasmids containing the gene in the 
pENTR222 entry vector were obtained through the Invitrogen Gateway ORFeome 
collection (Figure 1).  The remaining 49 genes were sub cloned from a variety of vectors 
into one of the Invitrogen Gateway entry vectors (for complete list of original vectors and 
sources see Appendix 1, for list of primers used for TOPO cloning see Table 2).  Clones 
were selected 
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Figure 1: Flowchart showing steps of making the Hsa21 Gene Expression Clone-set and 
the screen of the set in zebrafish 
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Table 1: List of primers used for TOPO cloning  
Gene 
Symbol TOPO Forward Primer TOPO Reverse Primer 
B3GALT5 
CACCATGGCTTTCCC 
GAAGATGAGATTG 
TCAGACAGGCGGACA 
ATCTTC 
BACH1 
CACCATGTCTCTGAG 
TGAGAACTCG 
TGCAAGTTTACTCAT 
CAGTAGTACATTTATC 
Col6a1 
CACCATGAGGGCGGC 
CCGTGCTCTGC 
CTAGCCCAGCGCCAC 
CTTCCTG 
DOPEY2  CACCATGGTGACAGT 
CCCTCCCATTGCT 
TCAGACACCATGATG 
GGCCAC 
DSCAM CACCATGTGGATACT 
GGCTCTCTCCTT 
GAGCTCGAATTCGTT 
TAAACTACCAGGGTGTAAG 
DSCR10 CACCATGCAGATTGT 
GCAGGGGTTC 
TCACACAGGCATACA 
CACGG 
DYRK1A 
CACCATGCATACAGG 
AGGAGAGACTTCA 
CTATTACGAGCTAGC 
TACAGGACTCTGTT 
ITSN1 
CACCATGGCTCAGTT 
TCCAACACCT 
CTACGGCTCATCAAA 
CAACTG 
LCA5L  
CACCATGTCTTTGGC 
TGATCTAAC 
AAACCAGAATGCATT 
AGGATATTGA 
LRRC3 
CACCATGGGCACCGT 
GCGCCCACCTCG 
CTAGGGCCCCGGGCC 
GATGGGG 
MCM3AP 
long 
CACCATGAACCCAAC 
TAATCCTTTCAGTG 
GCTCAAATGTCCACC 
ATGTCT 
MRPL39 
CACCATGGAGGCGCT 
GGCCATGGGTTCC 
TTAGGTAGATGTACA 
TTCCTC 
PLAC4 
CACCATGGGGACAAC 
AAGGAGTATCC 
TCAGGACTGGGGGAC 
TGAAGAGAC 
SIM2 
CACCATGAAGGAGAA 
GTCCAAGAATG 
AAGCCCTACTTAGAA 
GCAGAAAGAG 
SYNJ1-145 
CACCATGGCGTTCAG 
TAAAGGATTC 
CCTGTTACCCTGATG 
GTTGC 
SYNJ1-170 
CACCATGGCGTTCAG 
TAAAGGATTC 
GCGTTATCTTTCTGT 
AAAGTCCAGTG 
TRPM2 
CACCATGGAGCCCTC 
AGCCCTGAGG 
TCAGTAGTGAGCCCC 
GAAC 
TTC3 
CACCATGGACAATTT 
TGCTGAG 
TGACTACCTAGAAGA 
GCAGGAAG 
USP25 
CACCATGACCGTGGA 
GCAGAACGTGC 
GCACGTTCTGCTCCA 
CGGTCAT 
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using kanamycin and then sequenced to confirm presence of gene.  All genes in the entry 
vector were then sub-cloned into the pCS2Des vector (Invitrogen) using LR clonase as 
previously described [39].  Genes in the pCS2+ vector were selected for by ampicillin.  
The pCS2+ vector clone set, named the Hsa21 Gene Expression Set, is available for 
purchase through AddGene. 
 
Results/Discussion 
Development of the clone-set 
 We assembled a set of Hsa21 cDNA clones consisting of 169 Hsa21 genes, 149 
that are highly conserved between human and mouse and 20 human specific genes 
[11,12].  Two genes, SYNJ1 and MCM3AP, were each represented by two isoforms for a 
total of 171 cDNAs (Appendix 1). Cloning into the Invitrogen Gateway™ entry vector 
allows efficient sub-cloning of large sets of genes into destination vectors suitable for 
many experimental designs such as transcription, mammalian expression and the addition 
of tags. The pCS2+ vector contains an SP6 promoter that supports transcription of RNA 
and a CMV promoter for expression of transfected plasmid in mammalian cells and 
tissues. 
 
Genes included in clone-set 
Predominately, this study set consists of genes that are conserved in mice.  Of the 169 
genes included, 147 were curated from lists of conserved genes from Gardiner and 
colleagues [11,12].  Seventeen of the remaining genes are on Sturgeon and Gardiner’s list 
of Hsa21 genes that are considered to have associated RefSeq proteins but are not 
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conserved [12], of which eleven are found in a list of human specific genes [11].  Six 
genes are included in the clone-set that are not in Sturgeon and Gardiner's list of genes on 
Hsa21, but are listed in the NCBI database as being on Hsa21 (TPTE, TMPRSS3, BAGE, 
BAGE4, C21ORF37, and C21ORF125; accessed April 15, 2013 [40]).  TPTE was found 
to be conserved in position but minimally conserved in sequence with mouse Tpte 
(BLAST with 76% sequence identity over 55% coverage through the mRNA). TMPRSS3 
was found to be highly conserved with mouse Tmprss3, with 86% identity over 60% of 
the mRNA. BAGE and BAGE4 are two members of the B melanoma antigen family, with 
no conservation in mouse.  Lastly, there are two ORFs, C21ORF37 and C21ORF125, 
which have been classified as non-coding RNA.   
 
Of the 164 genes considered to be highly conserved with mouse, 17 genes are not 
included in our screen.  Five of those genes are microRNAs, which have to be 
specifically processed for proper function, and it was determined that our assay in fish 
would not allow for proper processing, additionally the 3’ untranslated region is not 
expected to have the degree of sequence conservation necessary for proper microRNA 
function.  One gene is listed as unknown gene type in the NCBI database with no RefSeq 
protein associated (which was listed in Sturgeon and Gardiner 2011 as having a RefSeq 
protein).  Some of the genes had large coding regions that made cloning difficult, e.g. 
SON.  And others of the genes were ORFs that were difficult to obtain. 
 
This set of Hsa21 genes should prove to be a useful tool for the DS community.  The 
ability to efficiently and quickly sub-clone the set into other destination vectors allows 
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for flexibility in a research paradigm, such that modifying genes with fluorescent tags can 
be done in a high throughput manner [35,39].  Additionally, destination vectors have 
been developed with different promoters, including a CMV promoter for eukaryotic 
expression, an SP6 promoter for prokaryotic expression, as well as promoters for 
tissue/cell specific expression [35].  Vectors continue to be developed, meaning that this 
system, and this clone-set, will be useful for many different research labs. 
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CHAPTER 3: SCREENING THE HSA21 CLONE-SET IN ZEBRAFISH 
Introduction 
Interest in genotype-phenotype correlations has been ongoing among the DS community 
for decades, both using human patients as well as animal model systems.  In humans, 
individuals with partial trisomy 21 along with detailed phenotyping was used to attempt 
to narrow down the region of Hsa21 that might be critically involved in either DS as a 
whole, or in specific phenotypes of DS (e.g. CHD, AMKL, cognitive impairment or 
craniofacial features, [14,15,16,17,18]).  In many cases either it was not possible to 
accurately distinguish a critical region, or the critical region described is large enough to 
contain many genes that would all then need to be carefully and systematically examined, 
or multiple susceptibility regions were found [16,18].  The establishment of genotype-
phenotype correlations in humans is complicated by the lack of large enough sample 
sizes [14], not having enough patients with some of the specific phenotypes of interest, or 
in some cases the partial trisomy was part of larger complex genomic rearrangements that 
would complicate the  analysis [17]. The genetic heterogeneity inherent in humans also 
complicates analysis, particularly of phenotypes that have variable penetrance and 
severity. 
 
The many mouse models that have different trisomic segments that correspond to Hsa21 
allow for potentially a more precise genotype-phenotype correlation since it’s possible to 
obtain large enough sample sizes, and due to the inbred nature of mice there is less 
genetic heterogeneity masking trisomic effects [24,29].  But even with mice, there are 
limitations to their use in genotype-phenotype correlations.  The use of mice with 
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successively smaller trisomic regions can be used to narrow a region, but phenotypes may 
be due to multiple non-contiguous genes and spatial-temporal expression of those genes 
could affect the presentation of the phenotype.  Transgenic models of single Hsa21 genes 
can be used to examine the effects of single gene over-expression on the phenotype to 
narrow down causative genes, or genes that may play a role in many DS phenotypes [41].  
These transgenic models are costly and time intensive to make and assess, inhibiting their 
use in a high throughput unbiased manner. 
 
Zebrafish are a valuable model to examine early development.  The large number of 
progeny allow for the use of hundreds of embryos per experiment, and the short 
generation time (most structures are formed by 5 DFP [34]) make zebrafish an ideal 
system for a large genetic screen.  I used the Hsa21 Gene Expression clone-set to 
examine the effects of expression of individual Hsa21 genes on early development by 
injecting the mRNA into zebrafish embryos and screening for phenotypes at 5 DPF. 
 
Methods 
In vitro transcription of mRNA 
Plasmids containing genes from Hsa21 were transcribed in vitro using the mMessage 
mMachine SP6 kit.  Plasmids were linearized with the appropriate restriction enzyme 
(see Appendix 2 and Figure 1), then purified by precipitation.  Genes were transcribed 
with mMessage mMachine SP6 polymerase then treated with DNAse1.  mRNA was 
purified with lithium chloride.  mRNA quality and quantity was confirmed with a 
formaldehyde agarose gel and the Nanodrop8000 respectively. 
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Zebrafish maintenance and injections 
Zebrafish were raised in the FINZ center at the Institute for Genetic Medicine (Johns 
Hopkins University) as previously described [42].  Zebrafish were maintained at 28°C.  
Male and female Tubingen zebrafish were placed in the same breeding tank in the 
morning and embryos were collected 30 minutes later.  One hundred embryos were then 
injected at the 1-4 cell blastulae stage using a Ziess Stemi 2000 microscope and PV820 
Pneumatic picopump injector.  For each gene, there were two concentrations of mRNA 
injected: 10pg and 50pg or 50pg and 100pg.  A cut off of 10% penetrance was used for 
all phenotypes except for rare phenotypes that are not observed in controls, e.g. cyclopia 
and craniofacial abnormalities.  All candidates were re-injected at 100pg. Embryos were 
raised to 5 days post fertilization and then phenotyped using a Nikon SMZ1500 
microscope and imaged with NIS Elements Imaging Software.  After imaging, embryos 
were fixed in 4% PFA overnight then transferred to 100% methanol for storage at -20°C. 
 
Morpholino rescue  
Translation inhibiting antisense morpholinos (MO) were designed against the human 
sequence for the genes SOD1, RWDD2B, and CCT8, designed to bind to the ATG start 
codon of the mRNA using Gene Tools (Philomath, OR): SOD1 5’-
GCACGCACACGGCCTTCGTCGCCAT-3’; RWDD2B 5’-
GCTGCATGGACAGCTCAATTTTCAT-3’; and CCT8 5’-
GAGCCTTGGGAACGTGAAGCGCCAT-3’.  The MOs were checked using BLAST to 
ensure sequence specificity to the human homologue and that they did not match any 
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other sequence in the human or zebrafish genome.  For JAM2, the MO used was 
designed against the zebrafish homologue, Jam2a, as previously described [43].  For each 
gene, 100 embryos were injected with 2ng MO, 100 embryos were injected with 100pg of 
mRNA and 100 embryos were injected with both 2ng MO and 100pg mRNA. Also, 100 
un-injected embryos were used as a control.  Embryos were examined at 5 dpf for SOD1 
and RWDD2B, 4 dpf for CCT8, and 24 hpf for JAM2. The embryos were assayed at the 
earliest stage at which the phenotype was most easily identified. 
 
Histogram 
All plates were examined for the presence of any abnormal fish, and a penetrance (% of 
total embryos) was calculated for each plate independently.  Penetrances were grouped in 
a histogram, with the y-axis representing the number of plates that had a specific 
penetrance of abnormal fish.  Non-candidates were plotted separately from candidates.  
An average penetrance was calculated for the non-candidates, the twenty-three and ten 
candidates.  The candidates (ten and twenty-three) were compared to the non-candidates 
using a Student t-test for significance. 
 
Statistical Tests 
For the morpholino rescue experiment and the combinatorial injections, penetrance 
differences were examined using a Fisher’s Exact test with a p< 0.05 required for 
significance.  For the histogram data, Student T-tests were used to compare the non-
candidates average penetrance to the twenty-three candidates and ten candidates 
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Results 
Zebrafish screen 
RNAs were synthesized from 171 Hsa21 cDNA clones and each was injected into one 
hundred 1-2 cell zebrafish embryos at each of two concentrations (either 10pg and 50pg, 
or 50pg and 100pg, see Appendix 2). The embryos were allowed to develop through 5 
DPF and screened for gross morphological changes.  We compared the frequency of a 
given defect in injected fish compared to controls. Observed phenotypes included U-
shaped somites and cyclopia, both of which are associated with defects in the Shh 
pathway and the ciliome; craniofacial abnormalities and pigment differences, which may 
be related to aberrations of neural crest cells; and pericardial edema (Figure 2).  In every 
case, the phenotype was incompletely penetrant, i.e., fewer than 100% of the embryos 
were affected.  A wide range of penetrance was observed for different genes, and in 
independent injection cohorts with the same gene.  
 
Of the 171 RNAs, twenty-three showed a phenotype after the initial screen, including 
fourteen that gave a Shh/ciliome - related phenotype (eight with U-shaped somites and 
six with cyclopia), seven with phenotypes related to neural crest cells (four with 
craniofacial abnormalities and three with pigment differences), one gene that resulted in a 
pericardial edema phenotype and one that produced a fin phenotype (Appendix 2 and 
Table 2).  Fresh RNA was prepared from these first round candidates and the injections 
were repeated.  
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Figure 2: Examples of phenotypes observed in screen.  Control embryos are on the left 
panel and injected embryos are on the right panel. Somites: RWDD2B 100pg injected 
embryos at 24 hpf with dashed lines to highlight somitic boundaries.  Cyclopia: 
C21ORF84 100pg injected embryos at 5 dpf.  Pigment: CCT8 100pg injected embryos at 
4 dpf, arrows indicating melanocytes.  Heart: JAM2 100pg injected embryos at 48 hpf.
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Table 2: Twenty-three candidates from first pass of screen 
Phenotype category Description # Candidates 
U-shaped Somites Somites with characteristic U shape 8 
Cyclopia Single large eye 6 
Craniofacial abnormalities Small/missing mandible; skull abnormalities 4 
Pigment abnormalities Floating melanocytes; reduced pigment in eye 3 
Heart Pericardial edema 1 
Other Tail/fin abnormalities 1 
 
 
24 
  
Ten candidates robustly recapitulated the original phenotypes; seven from the 
Shh/ciliome groups, two with neural crest related phenotypes, and the gene resulting in 
pericardial edema (Figure 2 and Table 3).   
 
Phenotypic rescue via Morpholinos 
We performed a morpholino (MO) rescue experiment with four candidate genes to 
determine whether the phenotypes observed are due to the expression of the specific 
RNA and not to RNA toxicity. Translation-blocking MOs were designed against the 
human copies of SOD1, RWDD2B or CCT8 and against the zebrafish orthologues of 
JAM2.  One hundred embryos were injected with just RNA, just MO, and RNA +MO. 
For all four genes, injection of the RNA alone produced significantly higher penetrance 
than the uninjected controls, the MO alone or the MO+RNA injected embryos (p<0.05; 
Figure 3).  For SOD1, RWDD2B, and CCT8, the MO+RNA was not significantly 
different from the controls. JAM2 MO+RNA showed heart edema significantly more 
frequently than controls, but was significantly less than the RNA alone. 
 
Dosage and gene expression patterns 
All ten candidates were injected at three or more concentrations ranging from 10pg to 
200pg but no linear correlation between dosage and penetrance was observed (Figure 4).   
 
 
25 
Table 3: Final candidate list of genes that recapitulated the phenotype after re-injection. 
Gene Symbol Phenotype Penetrance Expression in mouse [44] 
SOD1 U-somites 10-35% Expressed ubiquitously at 
E10.5, strongly expressed in 
muscles at E14.5 
RWDD2B U-somites 15-31% Expressed ubiquitously at 
E10.5 
RRP1 U-somites 15-40% Weakly expressed in somites 
at E10.5 [45] 
PCBP3 U-somites 8-13% Expressed in brain and spinal 
cord at E14.5 
YBEY U-somites 12-19% Expressed ubiquitously at 
E10.5 
C21orf84 U-somites/ 
Cyclopia 
9-23% U-somites 0-
7% cyclopia                                  
human specific [11] 
POFUT2 Cyclopia 0-4% Strong in face and pharyngeal 
arches at E9.5 [45] 
CBR3 Craniofacial 7-10% Expressed ubiquitously at 
E10.5, strong in cartilage at 
E14.5 
CCT8 Pigment 15-40% Expressed ubiquitously at 
E10.5 
JAM2 Pericardial 
Edema 
20-60% High expression in human 
heart [46] 
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Figure 3: Four of the 10 candidates (SOD1, RWDD2B, CCT8, and JAM2) were co-
injected with translational blocking morpholino.  100pg RNA was injected alone, 2 ng 
MO alone, or both were co-injected, using un-injected embryos as a control. * Fisher’s 
Exact Test p-value <0.05 
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Figure 4: Penetrance of phenotypes of candidate genes at different dosages. 
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Eight of the ten candidates have zebrafish homologues, the exceptions being C21ORF84 
and CBR3.  Seven of those eight genes have representative in situ hybridization data 
available in the ZFIN catalog.  For most of the candidates, the gene was shown to be 
expressed in the structure affected by RNA injection. Sod1, Rrp1, Ybey are expressed in 
somites; Cct8 is expressed ubiquitously; and Jam2 shows expression in the region of the 
developing heart (Table 3).  Pofut2 is expressed in the brain and eye, which is consistent 
with its cyclopia phenotype.  However, Pcbp3, which caused U-shaped somites, is not 
detectable by in situ hybridization in early development and Rwdd2b was not present in 
the ZFIN catalog. Nine of the ten candidates have mouse orthologues whose expression 
has been examined at mid-gestation, and in each case, the genes are expressed in the 
corresponding locations during embryonic development in mouse (Table 3, [44,45]).  
C21ORF84 is human specific, but shows homology with primate [11]. 
 
Histogram of phenotypic data 
Some phenotypes, e.g. U-shaped somites and edema, are found frequently at low 
penetrance in many injections as well as in the control embryos.  Other phenotypes such 
as cyclopia and craniofacial abnormalities occur rarely in injected embryos and never in 
control embryos.  To understand the distributions penetrance of the more common 
phenotypes, the frequency of observing abnormal embryos was evaluated for non-
candidate genes and candidate genes separately, the spread of the penetrance of 
abnormalities examined. All injected embryos were examined for any abnormal embryos 
and the penetrance of abnormality was determined both for embryos that were injected 
with genes that did not cause phenotypes as well as for embryos injected with the 
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candidate genes.  The number of plates of embryos that had a particular penetrance was 
visualized as the frequency in a histogram (Figure 5).  
 
Penetrance of abnormality among the non-candidates was examined from 281 plates of 
injected embryos, and averaged to 9.57% abnormal.  All 175 injected plates from the 
twenty-three  candidates was also examined for all abnormalities and prepared in a 
similar histogram, with an average of 16.3% abnormal embryos (t-test, p= 7.1E-10 
compared to non-candidates).  The ten final candidates were examined separately from 
the thirteen candidates that did not replicate and of those 125 plates, there was an average 
of 17.2% abnormal embryos (t-test, p=6.57E-09 compared to non-candidates).  The 
candidate genes clearly have a right shift in distribution of penetrance compared to the 
non- candidates.  These data suggests that our cut off of 10% for most of the phenotypes 
(excluding the rare phenotypes, such as cyclopia) was sufficient to account for the 
presence of general abnormalities within the embryo population. 
 
Discussion: 
We have conducted the first large-scale study of the effects of Hsa21 expression on early 
embryogenesis. Previous analyses of Hsa21 gene expression in early development used in 
situ hybridization [44,47] or microarrays to examine the localization, timing and levels of 
Hsa21 gene up-regulation [48].  In this study we used a functional assay in zebrafish to 
find candidate genes with effects on early development in a systematic approach. This 
stage of development is difficult to study in other vertebrates. Ten genes were implicated 
in affecting the ciliome/Shh signaling, NCC or the heart. Several of the genes found  
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Figure 5: Histogram of frequency of observed penetrance of abnormalities from zebrafish 
screen.  A. the 148 genes in which no observable phenotype was determined.  B. Twenty-
three candidates from the first pass of the screen. C. The ten final candidates.  Red dashed 
line represents the average penetrance of the non-candidate genes for comparison to the 
candidates.
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through this screen have little or no known function, and none have a known role in 
either the ciliome/Shh signaling pathway or NCC generation and development. 
 
In this screen we identified ten genes that are candidates for further study.  CCT8 and 
CBR3 are associated with pigment abnormalities and craniofacial abnormalities, 
respectively, which suggests a role in the proliferation, migration or differentiation of 
NCC.  CCT8 encodes a chaperonin that is localized to the cytoplasm [49], and has a 
potential role in histone modification due to its association with histone deacetylase C3 
(HDAC3 [50]).  CBR3 is a carbonyl reductase gene, for which there is little information 
about function. (Although it is similar structurally to CBR1, the two genes likely have 
different substrates [51]).  Neither of these genes are currently associated with regulation 
of NCC. JAM2-injected embryos had a repeatable and robust pericardial edema 
phenotype, indicating a possible role in heart development, which is further supported by 
evidence in the mouse that it is expressed in fetal and adult heart, and may be involved in 
cardiac inflammatory conditions [46].  There's evidence that JAM2 is involved in 
lymphocyte adhesion [52], so it’s possible that it facilitates edema through the immune 
pathway instead of affecting the development of the heart. 
 
Three of the genes identified in the screen (RWDD2B, YBEY and C21ORF84) have very 
little known information and no known function.  RWDD2B has been identified in a 
handful of large protein-protein interaction screens, with possible interactions with 
DDX19 [53], as well as a possible substrate for SRPK2, a serine/arginine protein kinase 
[54]. There is no information about C21ORF84, other than that it is described as a long 
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intergenic non-coding RNA.  In a yeast-two hybrid screen, Ybey was shown to have a 
protein-protein interaction with Gem, a GTP binding protein expressed in skeletal muscle 
[55].  These three genes, along with PCBP3, POFUT2 and RRP1 were found to have 
either U-shaped somites or cyclopia.  RRP1 is involved in the processing of rRNA [56].  
PCBP3 binds to C-rich pyrimidine regions of RNA, but no known established function 
has been shown, although it was a hypothesized role in post-transcriptional regulation 
[57]. POFUT2 is an O-fucosyltransferase, whose target protein substrates are components 
of the extra-cellular matrix [58]. SOD1 is another candidate for a possible Shh related 
phenotype due to its U-shaped somite phenotype.  Transgenic SOD1 mice had impaired 
muscle function as assessed by the rope grip test [59].  SOD1 is not known to play a role 
in Shh signaling, but it is expressed at the neuromuscular junction, which may indicate 
that it acts upstream of the Shh pathway [60,61]. In fact evidence suggests that mutations 
in Sod1 in mice (G93A, a common mutation used for the study of Amyotrophic lateral 
sclerosis) result in altered morphology of slow twitch and fast twitch muscle fibers, with 
the slow twitch fibers should a great variation in muscle fiber diameter with an over all 
shift towards smaller fibers in both slow twitch and fast twitch [62].  This could be 
analogous to the U-shaped somite phenotype in the zebrafish, which suggests that the 
effect of SOD1 on the U-shaped somite phenotype is related to its effect on the 
neuromuscular junction. 
 
 A negative result in the screen does not rule out contribution of that gene to DS.  Some 
mRNAS might have been inefficiently translated due to the fact that these are human 
mRNAs in fish.  Some human proteins may simply be unrecognizable to the fish, e.g., a 
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growth factor requires a specific receptor to function. Nonetheless, it was somewhat 
surprising that several Hsa21 genes that have been associated with dramatic phenotypes 
in mouse models of DS did not produce a phenotype in this screen. For example, 
DSCAM, a cell adhesion molecule that is involved in cell recognition [63] and has been 
implicated in both heart and neurogenesis defects in DS [64] but did not produce a 
phenotype here.  DYRK1A, a dual specificity kinase expressed during early neurogenesis 
that has been the subject of pilot trials for treatment of cognitive deficits in DS 
[65,66,67], also produced no phenotype in our screen. While these negative results were 
surprising, many types of refined screens with greater sensitivity and specificity are 
possible, taking advantage of transgenically marked zebrafish lines to ask specific 
questions about development of specific cells and tissues.   
 
Negative results in the screen could also result from stoichiometric issues.  Results from 
the different dosages of the ten final candidate genes did not show a significant difference 
in penetrance due to dosage, suggesting that the system is being saturated; and these 
concentrations are similar to other studies [68,69].  However, there is still the possibility 
that genes that gave negative results at 10pg and 50pg may in fact have shown a response 
at 100pg or more.  And in fact, some genes (notably transcription factors) have been 
reported anecdotally to produce phenotypes at very low concentrations that are not 
present when much more mRNA is injected; there is not currently a robust explanation 
for such a phenomenon.  
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Although this screen is purely observational, these data provide evidence for possible 
roles in the Shh pathway, NCC regulation and the heart.  Further characterization of these 
candidates could provide functional information for genes, some of which have no 
functions described.  In a more candidate based approach, these genes would likely have 
been missed.
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CHAPTER 4: PAIR-WISE COMBINATORIAL INJECTIONS OF SHH 
RELATED CANDIDATE GENES 
Introduction 
 As previous studies have shown, there are multiple regions of Hsa21 that are responsible 
for the many DS features, indicating that many features result from dosage imbalance of 
more than one gene [7,13,24,27].  These genes individually may have small or no effect, 
but together can have a larger effect on one or more developmentally important pathways 
[27,70]. A benefit of the zebrafish model is that this possibility can be evaluated in a pair-
wise fashion in a manner that is more technically difficult in mice. To evaluate this, I 
performed pair-wise injections of Hsa21 genes to evaluate their ability to cause a 
phenotype in combination.  To perform pair-wise injections of 171 cDNAs would require 
>14,000 injections, which was not feasible.  Instead I focused on the largest group of 
candidates from the screen: genes that gave a Shh related phenotype of either U-shaped 
somites or cyclopia. 
 
In the somites, the Shh pathway activates myf5 which regulates myogenesis [71].  Shh is 
required for myogenesis maintenance and controls the cell fate decision between fast 
muscle and slow muscle.  Absence of Shh leads to loss of slow muscle fibers and the 
level of Shh signaling affects the induction of muscle pioneer cells within the slow 
muscle fibers, with higher levels of signaling required for muscle pioneer cells than for 
the non-pioneer slow muscle [72].  Changes in level of Shh activation affect the 
differentiation of the different classes of muscle fibers, leading to the loss of the muscle 
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pioneer cell and increased fast muscle fibers, which in turn causes the somites to become 
U-shaped.   
 
In zebrafish, there are a number of mutant lines that are called “you-type” mutations due 
to the presence of U-shaped somites [73].  Many of the you-type mutations were found to 
occur in genes that are part of the Shh pathway. For example,  sonic you, syu, was 
determined to be a mutation in shh-a; you-too, yot, is a mutation in gli2; slow muscle 
omitted, smu, is a mutation in smo, [73,74]).  Additionally, when either of the two 
zebrafish orthologues for SHH, shh-a and shh-b, are knocked down using MO, the 
embryos exhibit U-somites and when both are knocked-down the fish developed 
cyclopia, as well [75].  This indicates that the presence of U-shaped somites or cyclopia 
might reflect abnormal regulation of the Shh pathway.  Of the ten final candidates, seven 
gave phenotypes relating to the Shh pathway.  These genes had either U-shaped somites 
and/or cyclopia. 
 
To look for possible additive effects of over-expression, the seven genes giving Shh-
related phenotypes were injected in a pair-wise fashion, using C21ORF84 as the 
reference gene that was co-injected with the other six genes.  C21ORF84 was the only 
gene that had both cyclopia and U-somites. 
 
Methods: 
Pair-wise injections: 
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RNA from C21ORF84 was co-injected with RNA from the following genes: SOD1, 
RWDD2B, RRP1, PCBP3, POFUT2, and YBEY.  For each experiment, each gene was 
injected individually at 100pg into 100 embryos, and then co-injected at 100pg of each 
RNA for a total of 200pg RNA. Uninjected embryos were used as controls.  Embryos 
were phenotyped at 24 hpf for the presence of U shaped somites and cyclopia.  Each co-
injection was performed twice.  
 
Combinatorial Injections: 
Plasmids containing DSCAM, SH3BGR, DCSR6, ADAMTS1, COL6A1, COL6A2, and 
Col18A1 were transcribed in vitro as previously described.  For SH3BGR, DCSR6, and 
ADAMTS1, 30 pg of each mRNA were combined for a total of 90 pg, injected into 100 
zebrafish embryos, and then examined for phenotypes at 5 DPF.  For DSCAM and 
SH3BGR, 50 pg each were combined for a total of 100pg RNA injected into 100 embryos 
and phenotyped at 5 DPF.  For COL6A1, COL6A2, and Col18A1, 50 pg each were 
combined for a total of 150pg of RNA injected into 100 embryos and phenotyped 5 DPF. 
 
Statistical Tests 
Penetrance differences were examined using a Fisher’s Exact test with a p< 0.05 required 
for significance. 
 
Results: 
We first examined the seven genes with Shh/ciliome phenotypes. For each set of pair-
wise injections, C21ORF84 was injected alone at 100pg, the second gene was injected 
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alone at 100pg, and both genes were injected together at 100pg each. Injection of 
C21ORF84 plus YBEY, PCBP3 or POFUT2 showed a significant increase in penetrance 
of U-shaped somites (Fig. 6, p<0.05 for each combination).  For two genes, SOD1 and 
RWDD2B, there was no significant difference between the individual injections and the 
combinatorial injection.  RRP1 alone had a penetrance of 42%, the highest of all the 
genes. This frequency was significantly reduced in embryos injected with RRP1 and 
C21ORF84.  
 
We also assessed candidate gene sets for possible combinatorial effects on developmental 
phenotypes. Co-injection of SH3BGR, DCSR6 and ADAMTS1 (30pg each), produced 
cyclopia in 3.6% and peri-cardial edema in a non-overlapping 3.6% of fish, whereas no 
control embryos were observed to have either edema or cyclopia, a strong trend though 
not formally significant (Fisher’s exact test, p=0.056 for either cyclopia or edema).  
Several Hsa21 gene combinations have been implicated in the high frequency of 
congenital heart disease in DS [46]. However, neither injection of all three collagens 
together (COL6A1, COL6A2, Col18A1) nor co-injection of DSCAM and SH3BGR  
produced a significant frequency of heart (or other) defects.  
 
Discussion: 
When using mouse models of DS, a subtractive approach is usually used, in which a 
phenotype is examined in the model with the largest trisomic content, and then 
continuing to use progressively smaller trisomic models until the phenotype is no longer 
observed.  Once a list of possible candidate genes is found, knock-out mice of the 
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Figure 6: Pair-wise combinatorial injections of Shh candidate genes.  C21ORF84 was co-
injected with 6 other genes to look for synthetic effects.  C21ORF84 was injected 
individually at 100pg RNA, the other gene was injected individually at 100pg RNA and 
then the two were injected together, 100pg each, for a total of 200pg RNA 
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candidates can be crossed with the trisomic mice and examined for absence of the 
phenotype [23].  In our study I chose an additive approach, starting with single genes that 
produced a phenotype and then performing pair-wise combinatorial injections using 
genes that gave related phenotypes.  I observed that some of the genes can interact in an 
additive manner, some have no apparent interaction and one pair had a compensatory 
interaction.  The compensatory interaction in which RRP1 and C21ORF84 together had 
lower penetrance than RRP1 alone supports the idea that it is the totality of the different 
effects of the many genes from Hsa21 that can cause a particular effect or phenotype.  
These pair-wise interactions could be expanded to include more combinations, including 
co-injecting genes that have similar proposed function or genes that are suspected to 
interact with each other (candidate based).  These could also be repeated in marked fish 
to narrow in on specific phenotypes. 
 
Compensatory interaction implies that over-expression of one gene in this pathological 
condition can balance the increased expression of another. Clearly the universe of 
possible individual gene effects and interactions in DS is large. The system described 
here provides an effective way to interrogate more complex interactions of non-
contiguous genes from the earliest stages of development.   
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CHAPTER 5. CONCLUDING REMARKS 
Many outcomes of trisomy 21 might result from perturbations of a limited number of 
pathways that are “common denominators” of multiple phenotypes [70].  An example is 
the Sonic hedgehog pathway (Shh) which has been shown to be down-regulated in the 
brains of mouse models of DS [76].  This results in cerebellar hypoplasia and hypo-
cellularity, which can be rescued by stimulation with SAG, a Shh agonist [76].  The 
attenuated response to Shh in Ts65Dn may also contribute to the craniofacial 
abnormalities resulting from the reduced proliferation and migration of neural crest cells 
(NCC) from the first pharyngeal arch in the developing mouse embryo [77].  Since Shh 
signaling is important in many aspects of prenatal development, down regulation of the 
pathway could result in defects in many tissues, including the brain, craniofacial skeleton, 
and heart, all of which are affected in individuals with DS [70].   
 
In the canonical Shh pathway, Shh binds to its receptor Patched (Ptc), which releases its 
repression on Smoothened (Smo), which moves  into the cilium [78,79,80]. There, Smo 
triggers the degradation of Suppressor of Fused (Sufu), which relieves Sufu’s binding of 
the Gli2 and Gli3 transcription factors, preventing them from being protealytically 
cleaved into their repressor forms. This leaves them in their activated form where they 
then move to the nucleus and act as transcription factors for down stream targets, 
including Gli1 and Ptc, as well as genes involved in cell cycle regulation [70,80]. 
 
Non-canonical Shh pathway activation can involve different components of the Shh 
pathway but with different down stream effects. For example, Ptc can inhibit  cyclin B1 
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translocation independent of Smo, affecting proliferation; independently Ptc can undergo 
caspase cleavage and induce apoptosis [79].   Shh can also act outside the Ptc-Smo-Gli 
pathway, possibly affecting NCC migration in a Smo-independent fashion.  Smo also has 
non-canonical activities, with recent research suggesting that it can act outside of the 
cilia, and that in fact its localization affects its activity; when localized to the cilia, Smo 
acts via the canonical pathway through Gli-mediated transcription, but when localized 
outside the cilium, Smo can affect a chemotactic response [81]. It’s possible that the 
maintenance of the correct ratio of Smo to either the cilium or other cellular locales is 
essential for proper development. 
 
Until recently there were no genes on Hsa21 that were known to play a direct role in the 
Shh pathway.  Evidence suggests that a cleavage product of APP may play a role in 
regulating the SHH receptor, PTCH [82].  
 
In zebrafish, the process of somitogenesis begins shortly after gastrulation with the 
segmentation of the paraxial mesoderm that flanks the notochord into blocks of cells of 
uniform size [73].  This process involves the action of the somite clock which involves 
oscillations of the notch pathway, along with her1 and her4 genes that regulate the timing 
of the segmentation, while opposing gradients of FGF/Wnt and retinoic acid regulate the 
position of segmentation [73,83].  The pre-somitic mesoderm (PSM) undergoes 
mesenchymal-epithelial transition, and the somites become mesenchyme surrounded by 
an epithelial layer, after which the somites are morphologically distinct [73,84].  The 
PSM then differentiates into sclerotome and myotome, eventually becoming the axial 
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skeleton and muscle.  The myotome differentiates from there into three classes of muscle 
fibers: fast muscle fibers that form deep in the core of the somites, while non-pioneer 
slow muscle fiber develop on the surface of the myotome and pioneer slow muscle 
(distinguished by the expression of Engrailed) differentiates adjacent to the notochord 
[73].  It is the careful balance of many developmental factors and pathways that regulate 
the differentiation of the myotome into their different fast and slow fibers.  Genes that 
affect this process of somitogenesis could alter the development of the somites, causing a 
morphological change, such as the U-shaped somites observed in this screen. 
 
Due to a partial genome duplication event approximately 250 million years ago, some 
human genes have multiple zebrafish orthologues [34]. This is the case for SHH. The 
zebrafish orthologues of SHH, shh-a and shh-b, are expressed in the notochord and floor 
plate and are a mitogen for somitic cells [85]. Among the you-type mutation strains, the 
U-somite phenotype in the syu embryos is milder than that observed in the yot and smu, 
which suggests that shh-b can compensate for shh-a [73].  When both shh-a and shh-b are 
knocked down with MOs, not only does the penetrance of the U-somites increase, but the 
embryos also begin to develop cyclopia [75].  
It is possible that the candidate genes that had U-shaped somites may affect the Shh 
pathway in a way that disrupts its induction of slow muscle fibers, resulting in the U-
somites.  These genes could be playing a role in the regulation or maintenance of the Shh 
pathway.  If they are involved in the Shh pathway during somitogenesis, they may also 
act in the pathway during other developmental events during embryogenesis.  Over 
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expression of these genes may be involved in the Shh pathway down regulation observed 
in the cerebellum and craniofacial development in mice. 
 
The additive effects observed in the pair-wise injections suggest that some of the Shh 
candidate genes may act in concert on the Shh pathway.  The genes not showing an 
additive effect may be affecting the pathway in ways that are independent of each other, 
or some of the genes could be acting outside of the canonical pathway.   Additionally, 
there is always the possibility that the genes are affecting the shape and development of 
the somites independently from Shh. An example is the case of the choker mutant 
zebrafish (cho) where evidence suggest that, although these embryos develop U-somites 
and are considered to be a you-type, they also develop melanophore abnormalities which 
are attributed to the defect in somite development which likely occurs downstream of the 
Shh induced differentiation of the slow muscle fibers [86].  Although the six genes that 
gave U-shaped somite phenotype may be affecting the Shh pathway, it is also possible 
that they are causing the U-shaped somites independent of the Shh pathway.  These genes 
should be explored further to rule out that possibility and confirm whether they have an 
effect on the Shh pathway. 
 
The Hsa21 Gene Expression clone-set described here will be a useful tool for the DS 
community.  Screening the clone-set in zebrafish produced a number of candidates with 
robust and replicable phenotypes with implications for effect on the Shh pathway, NCC, 
and heart development.  The Shh-related genes showed signs of additive effects in a pair-
wise set of injections, showing that this system can be used to study both the individual 
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effects of Hsa21 gene expression as well as combinatorial effects of multiple gene 
expression.  This study can be expanded upon by repeating the screen in transgenic 
zebrafish models as well as expanding upon the combinatorial injections using a 
candidate based approach as well as more unbiased methods. 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set  
Gene Name 
Zebrafish 
Plate/Well Gene Start (bp) Accession # 
ABCG1 P2/H3 43619799 NM_004915 
ADAMTS1 P1/B4 28208606 BC036515 
ADAMTS5 P1/C4 28290231 BC093777 
ADARB1 P2/F8 46493768 NM_015833 
AGPAT3 P2/E6 45285067 BC004219 
AIRE P2/A7 45705721 BC103511 
ANKRD20A11P P1/E1 15316090 Q8NFU9 
ANKRD30BP2  P1/C1 14410487 AF427490 
APP P1/H3 27252861 NM_000484 
ATP5J P1/F3 27088815 NM_001003696 
ATP5O P1/B9 35275757 NM_001697 
B3GALT5 P2/G1 40928369 BC104864 
BACE2 P2/D2 42539728 NM_012105 
BACH1 P1/C5 30566392 BC063307 
BAGE P1/B1 11057796 NM_001187 
BAGE4 P1/D1 14741931 NM_181704 
BRWD1  P2/B1 40556102 NM_001007246 
BTG3 P1/G2 18965971 NM_001130914 
C21orf119 P1/E6 33765439 NR_026845 
C21orf125 P2/G5 44869904 Q6ZR72 
C21orf128 P2/G3 43522244 BC063412 
C21orf2 P2/C7 45748827 NM_001271441 
C21orf37 P1/E2 18811208 NR_037585 
C21orf49 P1/E7 34144411 AK096601 
C21orf59 P1/A7 33951132 NM_021254 
C21orf67 P2/B8 46352729 AY035381 
C21orf77 P1/G6 33944548 BC027970 
C21orf88 P2/H1 40969074 BC119737 
C21orf91 P1/H2 19161284 BC015468 
C2CD2  P2/D3 43305221 BC062323 
CBR1 P1/D10 37442239 NM_001757 
CBR3 P1/E10 37507210 NM_001236 
CBS P2/C5 44473301 NM_000071 
CCT8 P1/A5 30428126 BC005220 
CHAF1B P1/G10 37757676 NM_005441 
CHODL P1/A3 19165801 NM_024944 
CLDN14 P1/H10 37832919 NM_012130 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set  
Gene Name 
Zebrafish 
Plate/Well Gene Start (bp) Accession # 
CLDN17 P1/E5 31538241 NM_012131 
CLDN8 P1/F5 31586324 NM_199328 
CLIC6 P1/A10 36041688 BC075706 
Col18a1 P2/E8 46825052 NM_001109991 
Col6a1 P2/A9 47401651 BC052575 
COL6A2 P2/B9 47518011 BC002484 
CRYAA P2/E5 44589118 NM_000394 
CRYZL1 P1/H8 34961647 NM_145858 
CSTB P2/C6 45192393 NM_000100 
CXADR P1/F2 18884700 NM_001338 
CYYR1 P1/A4 27838528 BC036761 
DIP2A P2/A10 47878812 NM_001146115 
DNAJC28  P1/E8 34860238 BC029509 
DNMT3L P2/H6 45666222 BC002560 
DONSON  P1/G8 34947783 BC043316 
DOPEY2  P1/F10 37529080 BC057081 
DSCAM P2/C2 41382926 AB384859 
DSCR10 P1/F12 39578250 BC093855 
DSCR3 P1/H11 38591910 BC110655 
DSCR4 P1/C12 39323728 NM_005867 
DSCR8 P1/D12 39493545 AA707621 
DSCR9 P1/G11 38580804 BC029827 
DYRK1A P1/A12 38739236 BC156309 
ERG P1/G12 39751949 NM_182918 
ETS2 P1/H12 40177231 NM_005239 
EVA1C P1/F6 33784314 BC038710 
FAM207A  P2/C8 46359955 NM_058190 
FAM3B P2/F2 42676139 NM_058186 
FTCD P2/C9 47556176 BC052248 
GABPA P2/A6 27106881 BC035031 
GART P1/F8 34870940 NM_175085 
GRIK1 P1/D5 30909254 BC031822 
HLCS P1/B11 38123493 NM_000411 
HMGN1  P2/C1 40714241 NM_004965 
HSF2BP P1/G3 44949072 NM_007031 
HSPA13  P1/H1 15743436 BC036370 
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 Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set 
Gene Name 
Zebrafish 
Plate/Well Gene Start (bp) Accession # 
HUNK P1/B6 33245628 NM_014586 
IFNAR1 P1/B8 34696734 NM_000629 
IFNAR2 P1/H7 34602206 BC002793 
IFNGR2 P1/C8 34757299 NM_005534 
IGSF5 P2/A2 41117334 BC004806 
IL10RB P1/A8 34638663 NM_000628 
ITGB2 P2/A8 46305868 BC005861 
ITSN1 P1/A9 35014706 BC116186 
JAM2 P1/E3 27011584 NM_021219 
KCNE1 P1/G9 35818988 BC036452 
KCNE2 P1/E9 35736323 BC112087 
KCNJ15 P1/E12 39529128 NM_002243 
KCNJ6 P1/B12 38996789 NM_002240 
LCA5L  P2/E1 40777770 BC031059 
LINC00313 (C21orf84) P2/H5 44881974 P59037 
LINC00314 (C21orf94) P1/D4 29385682 P59092 
LINC00478 (C21orf34) P1/D2 17442842 AA451643 
LIPI P1/F1 15481134 NM_198996 
LRRC3 P2/E7 45875369 BC119648 
LSS P2/E9 47608360 BC035638 
LTN1  P1/F4 30300466 BC150284 
MAP3K7CL P1/B5 30449792 BC008567 
MCM3AP 3' P2/G9 47655047 BC013285 
MCM3AP long P2/F9 47655047 BC104960 
MIS18A  P1/C6 33640530 NM_018944 
MRAP  P1/D6 33664124 NM_178817 
MRPL39 P1/D3 26957968 BC107719 
MRPS6 P1/C9 35445524 NM_032476 
MX1 P2/H2 42792231 NM_001144925 
MX2 P2/G2 42733870 BC035293 
N6AMT1 P1/E4 30244513 BC011554 
NCAM2 P1/C3 22370633 NM_004540 
NDUFV3 P2/A5 44299754 NM_001001503 
NRIP1 P1/B2 16333556 BC040361 
OLIG1 P1/G7 34442450 NM_138983 
OLIG2 P1/F7 34398153 BC036245 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set  
Gene Name 
Zebrafish 
Plate/Well Gene Start (bp) Accession # 
PAXBP1 P1/D7 34106210 BC030539 
PCBP3 P2/H8 47063608 BC012061 
PCP4 P2/B2 41239243 NM_006198 
PDE9A P2/G4 44073746 NM_001001567 
PDXK P2/B6 45138975 BC005825 
PFKL P2/B7 45719934 NM_002626 
PIGP  P1/D11 38435146 NM_153681 
PKNOX1 P2/B5 44394620 NM_004571 
PLAC4 P2/E2 42547158 BC093685 
POFUT2 P2/D8 46683843 NM_133635 
PRDM15  P2/C3 43218385 BC067102 
PRMT2 P2/C10 48055079 BC000727 
PSMG1  P2/A1 40546695 NM_003720 
PTTG1IP P2/H7 46269500 NM_004339 
PWP2 P2/G6 45527176 BC013309 
RBM11 P1/G1 15588451 NM_144770 
RCAN1 P1/H9 35885440 BC002864 
RIPK4  P2/B3 43159529 BC110617 
RIPPLY3 P1/C11 38378450 NM_018962 
RRP1 P2/D6 45209394 NM_003683 
RSPH1 P2/E4 43892596 BC101519 
RUNX1 P1/B10 36160098 BC069929 
RWDD2B P1/G4 30378080 NM_016940 
S100B P2/B10 48018875 NM_006272 
SAMSN1 P1/A2 15857549 NM_022136 
SCAF4  P1/A6 33043313 NM_020706 
SETD4  P1/C10 37406839 NM_001007259 
SH3BGR P2/F1 40817781 NM_001001713 
SIK1  P2/F5 44834395 BC038504 
SIM2 P1/A11 38071433 NM_005069 
SLC19A1 P2/G8 46913486 BC003068 
SLC37A1 P2/F4 43916128 NM_018964 
SLC5A3 P1/D9 35445870 NM_006933 
SMIM11 P1/F9 35747749 NM_058182 
SOD1 P1/H5 33031935 NM_000454 
SPATC1L P2/D9 47581062 NM_032261 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set 
Gene Name 
Zebrafish 
Plate/Well Gene Start (bp) Accession # 
SUMO3 P2/G7 46191374 NM_006936 
SYNJ1-145 P1/B7 33997269 AF009039 
SYNJ1-170 P1/C7 33997269 NM_003895 
TCP10L P1/H6 33948862 NM_144659 
TFF1 P2/C4 43782391 NM_003225 
TFF2 P2/B4 43766466 NM_005423 
TFF3 P2/A4 43731777 BC017859 
TIAM1 P1/G5 32361860 BC117196 
TMEM50B  P1/D8 34804792 NM_006134 
TMPRSS15  P1/B3 19641433 BC111749 
TMPRSS2 P2/A3 42836478 NM_005656 
TMPRSS3 P1/E11 38437942 NM_032405 
TPTE P1/A1 10906201 BC028719 
TRAPPC10  P2/F6 45432206 AB001517 
TRPM2 P2/D7 45770046 BC112342 
TTC3 P1/F11 38445571 BC137345 
U2AF1 P2/D5 44513066 NM_006758 
UBASH3A P2/D4 43824008 BC028138 
UBE2G2 P2/F7 46188955 NM_182688.2 
USP16 P1/H4 30396950 BC030777 
USP25 P1/C2 17102344 BC075792 
WDR4 P2/H4 44263204 NM_018669 
WRB P2/D1 40752170 NM_004627 
YBEY  P2/H9 47706267 NM_001006114 
ZNF295 P2/E3 43406940 BC063290 
ZNF295-AS1 P2/F3 43442113 Q8N0V1 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set continued 
Gene Name Catalog #  * Original vector 
ABCG1 IOH52605 pENTR221 
ADAMTS1 IOH22476 pENTR221 
ADAMTS5 OP#7939622 pCR4-TOPO 
ADARB1 IOH38242 pENTR221 
AGPAT3 IOH5155 pENTR221 
AIRE OP#40039054 pCR-BluntII-TOPO 
ANKRD20A11P IOH43458 pENTR221 
ANKRD30BP2  IOH50106 pENTR221 
APP IOH5590 pENTR221 
ATP5J IOH4502 pENTR221 
ATP5O IOH13236 pENTR221 
B3GALT5 OP#8143867 pCR4-TOPO 
BACE2 IOH13508 pENTR221 
BACH1 OP#MHS1010-9204253 pBluescriptR 
BAGE IOH50070 pENTR221 
BAGE4 IOH50065 pENTR221 
BRWD1  IOH39941 pENTR221 
BTG3 IOH10468 pENTR221 
C21orf119 IOH6691 pENTR221 
C21orf125 IOH35140 pENTR221 
C21orf128 OP#5207414 pCMV-SPORT6 
C21orf2 IOH23207 pENTR221 
C21orf37 IOH50121 pENTR221 
C21orf49 IOH50135 pENTR221 
C21orf59 IOH4573 pENTR221 
C21orf67 OP#40022796 pCR-BluntII-TOPO 
C21orf77 IOH11976 pENTR221 
C21orf88 OP#40119171 pCR-BluntII-TOPO 
C21orf91 IOH11236 pENTR221 
C2CD2  IOH40678 pENTR221 
CBR1 IOH3944 pENTR221 
CBR3 IOH5424 pENTR221 
 * Invitrogen Gateway ORFeome clones begin with IOH; Open Biosystems clones begin 
with OP 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set  
Gene Name Catalog #  * Original vector 
CBS IOH10211 pENTR221 
CCT8 IOH7383 pENTR221 
CHAF1B IOH13577 pENTR221 
CHODL IOH12081 pENTR221 
CLDN14 IOH12590 pENTR221 
CLDN17 IOH35308 pENTR221 
CLDN8 IOH12281 pENTR221 
CLIC6 OP#2648653 pCMV-SPORT6 
Col18a1 Harvard MmCD00319800 pCMV-SPORT6.1 
Col6a1 OP#6598940 pOTB7 
COL6A2 IOH4285 pENTR221 
CRYAA IOH40243 pENTR221 
CRYZL1 IOH22501 pENTR221 
CSTB IOH2908 pENTR221 
CXADR IOH10207 pENTR221 
CYYR1 OP#MHS1010-7508527 pCMV-SPORT6 
DIP2A IOH21776 pENTR221 
DNAJC28  IOH22569 pENTR221 
DNMT3L IOH4002 pENTR221 
DONSON  OP#5320969 pCMV-SPORT6 
DOPEY2  OP#5704600 pYX-Asc 
DSCAM Kazusa#FXC00331 pFK1 
DSCR10 OP#7939700 pCR4-TOPO 
DSCR3 OP#6157155 pCMV-SPORT6 
DSCR4 IOH40378 pENTR221 
DSCR8 IOH13220 pENTR221 
DSCR9 IOH28674 pENTR221 
DYRK1A OP#100061742 pENTR223.1 
ERG IOH26275 pENTR221 
ETS2 IOH10422 pENTR221 
EVA1C IOH26808 pENTR221 
FAM207A  IOH13437 pENTR221 
FAM3B IOH29166 pENTR221 
* Invitrogen Gateway ORFeome clones begin with IOH; Open Biosystems clones begin 
with OP 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set  
Gene Name Catalog #  * Original vector 
FTCD OP#6270063 pOTB7 
GABPA IOH27140 pENTR221 
GART IOH26153 pENTR221 
GRIK1 OP#4501004 pCMV-SPORT6 
HLCS IOH29186 pENTR221 
HMGN1  IOH4772 pENTR221 
HSF2BP IOH2965 pENTR221 
HSPA13  IOH22345 pENTR221 
HUNK Harvard HsCD00399347 pENTR223.1 
IFNAR1 IOH56150 pENTR221 
IFNAR2 IOH5316 pENTR221 
IFNGR2 IOH3856 pENTR221 
IGSF5 OP#3584645 pCMV-SPORT6 
IL10RB IOH4959 pENTR221 
ITGB2 IOH6210 pENTR221 
ITSN1 OP#40073781 pCR-BluntII-TOPO 
JAM2 OP#MHS6278-202840811 pDNR-LIB 
KCNE1 IOH22480 pENTR221 
KCNE2 OP#8327555 pCR4-TOPO 
KCNJ15 IOH13007 pENTR221 
KCNJ6 IOH42392 pENTR221 
LCA5L  OP#5271223 pBluescriptR 
LINC00313 (C21orf84) IOH34931 pENTR221 
LINC00314 (C21orf94) IOH43062 pENTR221 
LINC00478 (C21orf34) IOH50122 pENTR221 
LIPI HsCD00080183 from DNASU pENTR223.1 
LRRC3 OP#40115796 pCR-BluntII-TOPO 
LSS OP#5547173 pCMV-SPORT6 
LTN1  OP#8860138 pBluescriptIISK+ 
MAP3K7CL IOH3328 pENTR221 
MCM3AP 3' OP#MHS1011-75220  pOTB7 
MCM3AP long OP# MHS4426-99240373  pCR-XL-TOPO 
MIS18A  IOH28068 pENTR221 
* Invitrogen Gateway ORFeome clones begin with IOH; Open Biosystems clones begin 
with OP 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set 
Gene Name Catalog #  * Original vector 
MRAP  IOH40717 pENTR221 
MRPL39 OP#MHS1011-98053826 pDNR-LIB 
MRPS6 IOH13845 pENTR221 
MX1 IOH21990 pENTR221 
MX2 OP#5182160 pCMV-SPORT6 
N6AMT1 IOH12718 pENTR221 
NCAM2 IOH28826 pENTR221 
NDUFV3 IOH21750 pENTR221 
NRIP1 IOH25775 pENTR221 
OLIG1 IOH26795 pENTR221 
OLIG2 IOH62196 pENTR221 
PAXBP1 IOH21633 pENTR221 
PCBP3 IOH12489 pENTR221 
PCP4 IOH22123 pENTR221 
PDE9A IOH9807 pENTR221 
PDXK IOH5866 pENTR221 
PFKL IOH6888 pENTR221 
PIGP  IOH44755 pENTR221 
PKNOX1 IOH6384 pENTR221 
PLAC4 OP#7939530 pCR4-TOPO 
POFUT2 IOH39914 pENTR221 
PRDM15  IOH62935 pENTR221 
PRMT2 IOH4698 pENTR221 
PSMG1  IOH3819 pENTR221 
PTTG1IP IOH10419 pENTR221 
PWP2 IOH5155 pENTR221 
RBM11 IOH22581 pENTR221 
RCAN1 IOH5722 pENTR221 
RIPK4  OP#40034395 pCR-BluntII-TOPO 
RIPPLY3 IOH35236 pENTR221 
RRP1 IOH3452 pENTR221 
RSPH1 OP#8069025 pCR4-TOPO 
 * Invitrogen Gateway ORFeome clones begin with IOH; Open Biosystems clones begin 
with OP 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set 
Gene Name Catalog #  * Original vector 
RUNX1 OP#4008335 pCMV-SPORT6 
RWDD2B IOH12821 pENTR221 
S100B IOH4935 pENTR221 
SAMSN1 IOH22118 pENTR221 
SCAF4  IOH57303 pENTR221 
SETD4  IOH5697 pENTR221 
SH3BGR IOH45822 pENTR221 
SIK1  IOH29894 pENTR221 
SIM2 Harvard HsCD00346299 pCR-BluntII-TOPO 
SLC19A1 IOH4768 pENTR221 
SLC37A1 IOH37911 pENTR221 
SLC5A3 IOH36106 pENTR221 
SMIM11 IOH29335 pENTR221 
SOD1 IOH4089 pENTR221 
SPATC1L IOH14034 pENTR221 
SUMO3 IOH4668 pENTR221 
SYNJ1-145 Addgene 22291 pcDNA3-FLAG 
SYNJ1-170 Addgene 22292 pcDNA3-FLAG 
TCP10L IOH21795 pENTR221 
TFF1 IOH21839 pENTR221 
TFF2 IOH21844 pENTR221 
TFF3 IOH13105 pENTR221 
TIAM1 OP#40125747 pCR-XL-TOPO 
TMEM50B  IOH4187 pENTR221 
TMPRSS15  IOH36299 pENTR221 
TMPRSS2 IOH27076 pENTR221 
TMPRSS3 IOH35575 pENTR221 
TPTE IOH11625 pENTR221 
TRAPPC10  IOH28065 pENTR221 
TRPM2 OP#40069893 pCR-BluntII-TOPO 
TTC3 HsCD00342640 (Harvard) pCR-XL-topo 
U2AF1 IOH4817 pENTR221 
UBASH3A IOH11540 pENTR221 
UBE2G2 IOH45834 pENTR221 
USP16 IOH22293 pENTR221 
* Invitrogen Gateway ORFeome clones begin with IOH; Open Biosystems clones begin 
with OP 
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Gene Name Catalog #  * Original vector 
USP25 OP#30346400  pBluescriptR 
WDR4 IOH6391 pENTR221 
WRB IOH10553 pENTR221 
YBEY  IOH58675 pENTR221 
ZNF295 Harvard MMCD00346299 pCMV-Sport6 
ZNF295-AS1 IOH21603 pENTR221 
* Invitrogen Gateway ORFeome clones begin with IOH; Open Biosystems clones begin 
with OP 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set continued 
Gene Name cloning method entry vector 
ABCG1 NA pENTR221 
ADAMTS1 NA pENTR221 
ADAMTS5 RD cloning pENTR1a 
ADARB1 NA pENTR221 
AGPAT3 NA pENTR221 
AIRE RD cloning pENTR1a 
ANKRD20A11P NA pENTR221 
ANKRD30BP2  NA pENTR221 
APP NA pENTR221 
ATP5J NA pENTR221 
ATP5O NA pENTR221 
B3GALT5 TOPO cloning pENTR-Dtopo 
BACE2 NA pENTR221 
BACH1 TOPO cloning pENTR-Dtopo 
BAGE NA pENTR221 
BAGE4 NA pENTR221 
BRWD1  NA pENTR221 
BTG3 NA pENTR221 
C21orf119 NA pENTR221 
C21orf125 NA pENTR221 
C21orf128 RD cloning pENTR1A 
C21orf2 NA pENTR221 
C21orf37 NA pENTR221 
C21orf49 NA pENTR221 
C21orf59 NA pENTR221 
C21orf67 RD cloning pENTR1A 
C21orf77 NA pENTR221 
C21orf88 RD cloning pENTR1A 
C21orf91 NA pENTR221 
C2CD2  NA pENTR221 
CBR1 NA pENTR221 
CBR3 NA pENTR221 
CBS NA pENTR221 
CCT8 NA pENTR221 
CHAF1B NA pENTR221 
CHODL NA pENTR221 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set continued 
Gene Name cloning method entry vector 
CLDN14 NA pENTR221 
CLDN17 NA pENTR221 
CLDN8 NA pENTR221 
CLIC6 BP clonase pDONOR221 
Col18a1 BP clonase pENTR223.1  
Col6a1 TOPO cloning pENTR-Dtopo 
COL6A2 NA pENTR221 
CRYAA NA pENTR221 
CRYZL1 NA pENTR221 
CSTB NA pENTR221 
CXADR NA pENTR221 
CYYR1 BP clonase pDONOR221 
DIP2A NA pENTR221 
DNAJC28  NA pENTR221 
DNMT3L NA pENTR221 
DONSON  BP clonase pDONOR221 
DOPEY2  TOPO cloning pENTR-Dtopo 
DSCAM TOPO cloning pENTR-Dtopo 
DSCR10 TOPO cloning pENTR-Dtopo 
DSCR3 BP clonase pDONOR221 
DSCR4 NA pENTR221 
DSCR8 NA pENTR221 
DSCR9 NA pENTR221 
DYRK1A TOPO cloning pENTR-Dtopo 
ERG NA pENTR221 
ETS2 NA pENTR221 
EVA1C NA pENTR221 
FAM207A  NA pENTR221 
FAM3B NA pENTR221 
FTCD BP clonase pDONOR221 
GABPA NA pENTR221 
GART NA pENTR221 
GRIK1 BP clonase pDONOR221 
HLCS NA pENTR221 
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Gene Name cloning method entry vector 
HMGN1  NA pENTR221 
HSF2BP NA pENTR221 
HSPA13  NA pENTR221 
HUNK NA pENTR223.1  
IFNAR1 NA pENTR221 
IFNAR2 NA pENTR221 
IFNGR2 NA pENTR221 
IGSF5 BP clonase pDONOR221 
IL10RB NA pENTR221 
ITGB2 NA pENTR221 
ITSN1 TOPO cloning pENTR-Dtopo 
JAM2 RD cloning pENTR221 
KCNE1 NA pENTR221 
KCNE2 RD cloning pENTR1A 
KCNJ15 NA pENTR221 
KCNJ6 NA pENTR221 
LCA5L  TOPO cloning pENTR-Dtopo 
LINC00313 (C21orf84) NA pENTR221 
LINC00314 (C21orf94) NA pENTR221 
LINC00478 (C21orf34) NA pENTR221 
LIPI NA pENTR223.1  
LRRC3 TOPO cloning pENTR-Dtopo 
LSS BP clonase pDONOR221 
LTN1  RD cloning pENTR1a 
MAP3K7CL NA pENTR221 
MCM3AP 3' BP clonase pDONOR221 
MCM3AP long TOPO cloning pENTR-Dtopo 
MIS18A  NA pENTR221 
MRAP  NA pENTR221 
MRPL39 TOPO cloning pENTR-Dtopo 
MRPS6 NA pENTR221 
MX1 NA pENTR221 
MX2 BP clonase pDONOR221 
N6AMT1 NA pENTR221 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set continued  
Gene Name cloning method entry vector 
NCAM2 NA pENTR221 
NDUFV3 NA pENTR221 
NRIP1 NA pENTR221 
OLIG1 NA pENTR221 
OLIG2 NA pENTR221 
PAXBP1 NA pENTR221 
PCBP3 NA pENTR221 
PCP4 NA pENTR221 
PDE9A NA pENTR221 
PDXK NA pENTR221 
PFKL NA pENTR221 
PIGP  NA pENTR221 
PKNOX1 NA pENTR221 
PLAC4 TOPO cloning pENTR-Dtopo 
POFUT2 NA pENTR221 
PRDM15  NA pENTR221 
PRMT2 NA pENTR221 
PSMG1  NA pENTR221 
PTTG1IP NA pENTR221 
PWP2 NA pENTR221 
RBM11 NA pENTR221 
RCAN1 NA pENTR221 
RIPK4  RD cloning pENTR1a 
RIPPLY3 NA pENTR221 
RRP1 NA pENTR221 
RSPH1 RD cloning pENTR1A 
RUNX1 BP clonase pDONOR221 
RWDD2B NA pENTR221 
S100B NA pENTR221 
SAMSN1 NA pENTR221 
SCAF4  NA pENTR221 
SETD4  NA pENTR221 
SH3BGR NA pENTR221 
SIK1  NA pENTR221 
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Appendix 1: 169 genes/171 cDNAs in Hsa21 clone-set continued 
Gene Name cloning method entry vector 
SIM2 TOPO cloning pENTR-Dtopo 
SLC19A1 NA pENTR221 
SLC37A1 NA pENTR221 
SLC5A3 NA pENTR221 
SMIM11 NA pENTR221 
SOD1 NA pENTR221 
SPATC1L NA pENTR221 
SUMO3 NA pENTR221 
SYNJ1-145 TOPO cloning pENTR-Dtopo 
SYNJ1-170 TOPO cloning pENTR-Dtopo 
TCP10L NA pENTR221 
TFF1 NA pENTR221 
TFF2 NA pENTR221 
TFF3 NA pENTR221 
TIAM1 RD cloning pENTR1a 
TMEM50B  NA pENTR221 
TMPRSS15  NA pENTR221 
TMPRSS2 NA pENTR221 
TMPRSS3 NA pENTR221 
TPTE NA pENTR221 
TRAPPC10  NA pENTR221 
TRPM2 TOPO cloning pENTR-Dtopo 
TTC3 TOPO cloning pENTR-Dtopo 
U2AF1 NA pENTR221 
UBASH3A NA pENTR221 
UBE2G2 NA pENTR221 
USP16 NA pENTR221 
USP25 TOPO cloning pENTR-Dtopo 
WDR4 NA pENTR221 
WRB NA pENTR221 
YBEY  NA pENTR221 
ZNF295 BP clonase pDONOR221 
ZNF295-AS1 NA pENTR221 
 
62 
Appendix 2: Phenotypic data from Zebrafish screen for 171 clones  
Gene Symbol First conc. 
# surviving/ 
#injected 
Second 
conc. 
# surviving/ 
#injected 
ABCG1 10 61/99 50 55/98 
ADAMTS1 50 75/100 100 75/100 
ADAMTS5 50 87/100 100 84/100 
ADARB1 50 62/100 100 79/100 
AGPAT3 10 75/100 50 85/100 
AIRE 50 81/100 100 87/100 
ANKRD20A11P 50 74/100 100 82/100 
ANKRD30BP2  10 101/120 50 99/127 
APP 10 59/70 50 78/100 
ATP5J 10 63/101 50 40/140 
ATP5O 10 93/100 50 98/100 
B3GALT5 50 92/100 100 99/100 
BACE2 50 79/100 100 75/100 
BACH1 50 94/100 100 93/100 
BAGE 10 39/72 50 79/122 
BAGE4 10 104/120 50 100/120 
BRWD1  10 29/120 50 35/120 
BTG3 10 65/103 50 59/92 
C21orf119 50 82/100 100 77/100 
C21orf125 10 43/95 50 65/92 
C21orf128 50 62/89 100 58/90 
C21orf2 50 89/100 100 81/100 
C21orf37 10 75/100 50 75/100 
C21orf49 10 42/100 50 49/100 
C21orf59 10 121/146 50 98/126 
C21orf67 50 76/100 100 88/100 
C21orf77 10 0/106 50 34/82 
C21orf88 50 84/100 100 78/100 
C21orf91 10 162/220 50 109/138 
C2CD2  10 55/110 50 45/110 
CBR1 10 77/100 50 71/100 
CBR3 10 51/115 50 52/124 
CBS 10 54/117 50 52/106 
CCT8 10 60/77 50 83/100 
CHAF1B 10 85/100 50 63/100 
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Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol 
First 
conc. 
# surviving/ 
#injected 
Second 
conc. 
# 
surviving/ 
#injected 
CHODL 10 56/142 50 63/125 
CLDN14 10 2/120 50 0/120 
CLDN17 10 93/120 50 68/120 
CLDN8 50 92/100 100 66/100 
CLIC6 50 87/100 100 64/100 
Col18a1 50 92/100 100 97/100 
Col6a1 50 99/100 100 87/100 
COL6A2 10 69/100 50 72/100 
CRYAA 10 28/86 50 13/109 
CRYZL1 10 80/100 50 74/100 
CSTB 10 71/100 50 71/100 
CXADR 10 76/100 50 74/100 
CYYR1 50 78/100 100 94/100 
DIP2A 10 80/110 50 77/110 
DNAJC28  10 77/100 50 85/100 
DNMT3L 10 84/100 50 82/100 
DONSON  50 92/100 100 84/100 
DOPEY2  50 72/100 100 94/100 
DSCAM 50 96/100 100 95/100 
DSCR10 50 80/100 100 86/100 
DSCR3 50 89/100 100 86/100 
DSCR4 10 65/95 50 50/83 
DSCR8 10 57/135 50 74/150 
DSCR9 10 67/130 50 49/113 
DYRK1A 50 97/100 100 95/100 
ERG 10 22/67 50 7/50 
ETS2 10 46/100 50 52/100 
EVA1C 10 61/120 50 19/120 
FAM207A  10 77/100 50 74/100 
FAM3B 10 33/110 50 28/110 
FTCD 50 71/100 100 85/100 
GABPA 10 0/120 50 75/120 
GART 10 12/120 50 37/120 
GRIK1 50 56/75 100 53/75 
HLCS 10 68/100 50 81/103 
HMGN1  10 40/120 50 9/120 
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Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol 
First 
conc. 
# surviving/ 
#injected 
Second 
conc. 
# 
surviving/ 
#injected 
HSF2BP 10 97/121 50 84/103 
HSPA13  10 89/118 50 84/104 
HUNK 50 81/100 100 72/100 
IFNAR1 10 68/100 50 65/100 
IFNAR2 10 74/110 50 70/110 
IFNGR2 10 84/161 50 69/134 
IGSF5 50 87/100 100 76/100 
IL10RB 10 72/100 50 77/100 
ITGB2 10 43/109 50 53/81 
ITSN1 50 100/100 100 94/100 
JAM2 50 77/100 100 69/100 
KCNE1 10 27/50 50 0/50 
KCNE2 50 76/100 100 74/100 
KCNJ15 10 94/114 50 84/110 
KCNJ6 10 83/100 50 79/100 
LCA5L  50 95/100 100 92/100 
LINC00313 (C21orf84) 10 54/120 50 74/120 
LINC00314 (C21orf94) 10 78/103 50 83/110 
LINC00478 (C21orf34) 10 76/120 50 71/120 
LIPI 50 54/75 100 60/75 
LRRC3 50 96/100 100 92/100 
LSS 50 78/100 100 79/100 
LTN1  50 96/100 100 89/100 
MAP3K7CL 10 76/100 50 74/100 
MCM3AP 3' 50 72/100 100 88/100 
MCM3AP long 50 81/100 100 96/100 
MIS18A  10 71/115 50 56/119 
MRAP  10 0/120 50 18/102 
MRPL39 50 94/100 100 80/100 
MRPS6 10 20/73 50 3/103 
MX1 50 87/100 100 75/100 
MX2 50 88/100 100 88/100 
N6AMT1 10 12/120 50 2/120 
NCAM2 10 79/100 50 87/100 
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Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol 
First 
conc. 
# surviving/ 
#injected 
Second 
conc. 
# 
surviving/ 
#injected 
NDUFV3 10 67/100 50 77/100 
NRIP1 50 64/100 100 60/98 
OLIG1 10 76/110 50 68/100 
OLIG2 50 65/100 100 69/100 
PAXBP1 10 21/120 50 24/120 
PCBP3 10 78/143 50 71/117 
PCP4 10 60/114 50 76/127 
PDE9A 10 71/98 50 70/100 
PDXK 10 98/125 50 109/137 
PFKL 10 79/100 50 69/100 
PIGP  10 83/100 50 88/100 
PKNOX1 10 71/100 50 69/100 
PLAC4 50 90/100 100 93/100 
POFUT2 10 144/170 50 163/180 
PRDM15  10 41/110 50 70/110 
PRMT2 10 81/100 50 84/100 
PSMG1  10 54/120 50 22/120 
PTTG1IP 10 55/100 50 61/100 
PWP2 10 73/111 50 38/80 
RBM11 10 57/100 50 48/100 
RCAN1 10 71/128 50 18/107 
RIPK4  50 90/100 100 86/100 
RIPPLY3 10 76/120 50 85/120 
RRP1 10 73/114 50 67/96 
RSPH1 50 79/100 100 79/100 
RUNX1 50 84/100 100 86/100 
RWDD2B 10 75/100 50 91/100 
S100B 10 71/101 50 93/135 
SAMSN1 10 62/100 50 57/100 
SCAF4  10 1/120 50 0/120 
SETD4  10 0/115 50 11/45 
SH3BGR 10 68/120 50 73/120 
SIK1  10 17/46 50 70/90 
SIM2 50 90/100 100 80/100 
SLC19A1 10 91/113 50 67/95 
SLC37A1 50 87/100 100 85/100 
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Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol First conc. 
# surviving/ 
#injected 
Second 
conc. 
# surviving/ 
#injected 
SLC5A3 10 80/100 50 62/100 
SMIM11 10 40/50 50 45/50 
SOD1 10 93/100 50 87/100 
SPATC1L 10 57/100 50 64/100 
SUMO3 10 33/55 50 93/140 
SYNJ1-145 50 92/100 100 95/100 
SYNJ1-170 50 74/100 100 82/100 
TCP10L 10 36/120 50 37/120 
TFF1 50 86/99 100 81/98 
TFF2 10 75/96 50 103/134 
TFF3 10 15/115 50 10/100 
TIAM1 50 99/100 100 97/100 
TMEM50B  10 50/120 50 40/120 
TMPRSS15  10 75/100 50 75/100 
TMPRSS2 10 83/120 50 57/120 
TMPRSS3 10 68/98 50 65/81 
TPTE 10 72/96 50 69/88 
TRAPPC10  10 74/85 50 60/72 
TRPM2 50 71/100 100 82/100 
TTC3 50 87/100 100 78/100 
U2AF1 10 57/101 50 145/191 
UBASH3A 10 47/80 50 72/124 
UBE2G2 10 88/126 50 70/97 
USP16 10 51/110 50 0/110 
USP25 50 92/100 100 92/100 
WDR4 10 99/129 50 97/122 
WRB 10 90/120 50 65/120 
YBEY  10 62/100 50 80/100 
ZNF295 50 90/100 100 84/100 
ZNF295-AS1 10 85/100 50 84/100 
  
 
 
 
67 
Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol Observed Phenotype 
ABCG1  
ADAMTS1  
ADAMTS5  
ADARB1  
AGPAT3  
AIRE  
ANKRD20A11P  
ANKRD30BP2   
APP  
ATP5J  
ATP5O  
B3GALT5  
BACE2  
BACH1 3 cyclopia, 3 craniofacial abnormalities @ 100pg 
BAGE  
BAGE4  
BRWD1   
BTG3 2 with no jaw, 2 with small eyes @ 10pg 
C21orf119  
C21orf125  
C21orf128  
C21orf2  
C21orf37  
C21orf49  
C21orf59  
C21orf67  
C21orf77  
C21orf88  
C21orf91  
C2CD2   
CBR1  
CBR3 5 with abnormal skulls @ 50pg 
CBS  
CCT8 12 with abnormal melanocytes 
CHAF1B  
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Gene Symbol Observed Phenotype 
CHODL  
CLDN14  
CLDN17  
CLDN8  
CLIC6 11 & 10 Usomites at 50 & 100 pg 
Col18a1  
Col6a1 5 with jaw abnormalities @ 100pg 
COL6A2  
CRYAA  
CRYZL1  
CSTB  
CXADR  
CYYR1  
DIP2A  
DNAJC28   
DNMT3L  
DONSON   
DOPEY2   
DSCAM  
DSCR10  
DSCR3  
DSCR4  
DSCR8  
DSCR9  
DYRK1A  
ERG  
ETS2  
EVA1C 1 with cyclopia, 2 craniofacial abnormalities 
FAM207A   
FAM3B  
FTCD  
GABPA  
GART 6 with small heads and close set eyes 
GRIK1  
HLCS  
HMGN1  4 with missing melanocytes @ 50pg 
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Gene Symbol Observed Phenotype 
HSF2BP  
HSPA13   
HUNK  
IFNAR1 11 Usomites @ 50pg 
IFNAR2  
IFNGR2  
IGSF5  
IL10RB  
ITGB2  
ITSN1  
JAM2 11 & 13 with edema @ 50 & 100pg 
KCNE1  
KCNE2  
KCNJ15  
KCNJ6  
LCA5L   
LINC00313 (C21orf84) usomites and cyclopia at 100pg 
LINC00314 (C21orf94)  
LINC00478 (C21orf34)  
LIPI  
LRRC3  
LSS  
LTN1   
MAP3K7CL 8 Usomites @ 50pg 
MCM3AP 3'  
MCM3AP long  
MIS18A   
MRAP   
MRPL39  
MRPS6  
MX1  
MX2  
N6AMT1  
NCAM2  
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Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol Observed Phenotype 
NDUFV3  
NRIP1  
OLIG1 12 with abnormal fins 
OLIG2  
PAXBP1  
PCBP3 10 & 7 Usomites @ 10 & 50pg 
PCP4  
PDE9A  
PDXK  
PFKL  
PIGP   
PKNOX1  
PLAC4  
POFUT2 2 with cyclopia @ 50pg 
PRDM15   
PRMT2  
PSMG1   
PTTG1IP  
PWP2  
RBM11  
RCAN1  
RIPK4   
RIPPLY3  
RRP1 14 Usomites @ 50pg 
RSPH1  
RUNX1  
RWDD2B 15 & 20 with Usomites @ 10 & 50pg 
S100B  
SAMSN1 3&4 craniofacial abnormalities @ 10 & 50pg 
SCAF4   
SETD4   
SH3BGR  
SIK1   
SIM2  
SLC19A1  
SLC37A1  
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Appendix 2: Phenotypic data from Zebrafish screen for 171 clones 
Gene Symbol Observed Phenotype 
SLC5A3  
SMIM11  
SOD1 30 with Usomites @ 50pg 
SPATC1L 7 with reduced pigment in eye 
SUMO3  
SYNJ1-145  
SYNJ1-170  
TCP10L  
TFF1  
TFF2  
TFF3  
TIAM1  
TMEM50B   
TMPRSS15  7 with cyclopia @ 50pg 
TMPRSS2  
TMPRSS3  
TPTE  
TRAPPC10   
TRPM2  
TTC3  
U2AF1  
UBASH3A  
UBE2G2  
USP16  
USP25  
WDR4  
WRB  
YBEY  15 Usomites @ 50pg 
ZNF295  
ZNF295-AS1  
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